This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Oct;20(5):265-6.

doi: 10.1016/j.smim.2008.10.001. Epub 2008 Nov 1.

Tumor-specific immune responses

PMID: 18977672
PMCID: PMC3644555
DOI: 10.1016/j.smim.2008.10.001

Editorial

Tumor-specific immune responses

Hans Schreiber. Semin Immunol. 2008 Oct.

. 2008 Oct;20(5):265-6.

doi: 10.1016/j.smim.2008.10.001. Epub 2008 Nov 1.

Author

PMID: 18977672
PMCID: PMC3644555
DOI: 10.1016/j.smim.2008.10.001

No abstract available

PubMed Disclaimer

Similar articles

Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.
Spagnoli GC, Ebrahimi M, Iezzi G, Mengus C, Zajac P. Spagnoli GC, et al. Curr Opin Drug Discov Devel. 2010 Mar;13(2):184-92. Curr Opin Drug Discov Devel. 2010. PMID: 20205052 Review.
Mechanism of action of immunotherapy.
Disis ML. Disis ML. Semin Oncol. 2014 Oct;41 Suppl 5:S3-13. doi: 10.1053/j.seminoncol.2014.09.004. Epub 2014 Sep 6. Semin Oncol. 2014. PMID: 25438997 Review.
Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D, Jäger E, Bert F, Knuth A. Jäger D, et al. Cancer Chemother Biol Response Modif. 2001;19:385-93. Cancer Chemother Biol Response Modif. 2001. PMID: 11686025 Review. No abstract available.
Immune surveillance and anti-tumor immune responses: an anatomical perspective.
Zimmermann VS, Benigni F, Mondino A. Zimmermann VS, et al. Immunol Lett. 2005 Apr 15;98(1):1-8. doi: 10.1016/j.imlet.2004.09.005. Immunol Lett. 2005. PMID: 15790503 Review.
Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R. Baral R. Indian J Exp Biol. 2005 May;43(5):389-406. Indian J Exp Biol. 2005. PMID: 15900903 Review.

See all similar articles

Cited by

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. Stone JD, et al. Oncoimmunology. 2012 Sep 1;1(6):863-873. doi: 10.4161/onci.20592. Oncoimmunology. 2012. PMID: 23162754 Free PMC article.
Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
Yoon AR, Jiao A, Hong J, Kim B, Yun CO. Yoon AR, et al. Front Immunol. 2024 May 15;15:1360436. doi: 10.3389/fimmu.2024.1360436. eCollection 2024. Front Immunol. 2024. PMID: 38812516 Free PMC article.

References

1. Medawar PB. Advice to a young scientist. Basic Books (HarperCollinsPublishers); 1979. pp. 1–108. (Alfred P. Sloan Foundation Series).
1. Schreiber H. Chapter 48. Tumor Immunology. In: Paul W, editor. Fundamental Immunology. Lippincott-Williams & Wilkins; Philadelphia, PA: 2003. pp. 1557–1592.
1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27. - PubMed
1. Willimsky G, Blankenstein T. Sporadic immunogenic tumors avoid destruction by inducing T-cell tolerance. Nature. 2005;437:141–146. - PubMed
1. Willimsky G, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med. 2008;205(7):1687–700. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources